Bulletin of the American Physical Society
APS March Meeting 2018
Volume 63, Number 1
Monday–Friday, March 5–9, 2018; Los Angeles, California
Session L60: Poster Session II
11:15 AM,
Wednesday, March 7, 2018
LACC
Room: West Hall A
Abstract ID: BAPS.2018.MAR.L60.222
Abstract: L60.00222 : Computational Modeling of Neuromoscular Junction and Evaluation of A Novel Treatment For Neuromuscular Disease
Presenter:
Rozita Laghaei
(Pittsburgh Supercomputing Center, Carnegie Mellon Univ)
Authors:
Rozita Laghaei
(Pittsburgh Supercomputing Center, Carnegie Mellon Univ)
Scott Ginebaugh
(Department of Neuroscience, University of Pittsburgh)
Teja Peddada
(Department of Neuroscience, University of Pittsburgh)
Stephen Meriney
(Department of Neuroscience, University of Pittsburgh)
We used our control MCell model (validated by its ability to predict physiology) as a starting point for modeling the current treatments for the neuromuscular disease Lambert-Eaton Myasthenic Syndrome (LEMS). We modeled: A) the current treatment for LEMS, DAP (a potassium channel blocker), B) a newly developed drug (GV-58) that is a calcium channel gating modifier, and C) a combination of the two drugs. We evaluated the model-predicted effects on transmitter release of using different concentration combinations of each drug for future pre-clinical testing.
To cite this abstract, use the following reference: http://meetings.aps.org/link/BAPS.2018.MAR.L60.222
Follow Us |
Engage
Become an APS Member |
My APS
Renew Membership |
Information for |
About APSThe American Physical Society (APS) is a non-profit membership organization working to advance the knowledge of physics. |
© 2024 American Physical Society
| All rights reserved | Terms of Use
| Contact Us
Headquarters
1 Physics Ellipse, College Park, MD 20740-3844
(301) 209-3200
Editorial Office
100 Motor Pkwy, Suite 110, Hauppauge, NY 11788
(631) 591-4000
Office of Public Affairs
529 14th St NW, Suite 1050, Washington, D.C. 20045-2001
(202) 662-8700